| Featured Programs
Malignant Fungating Wounds (MFW)
Program: VT1953 Gel Status: Clinical Development
Malignant fungating wounds estimated affect up to 5%-14% of advanced cancer patients worldwide, causing severe pain, malodor, and social isolation. There are currently no approved drugs—patients rely on suboptimal off-label treatments.
VT1953 is a first-in-class gel designed to:
- Target DNA-gyrase to reduce the bacterial drivers of malodor.
- Inhibit the TLR-MD2 inflammation pathway to decrease pain and inflammation.
With its dual mechanism and strong clinical rationale, VT1953 has the potential to dramatically improve the quality of life for cancer patients suffering from MFW, while pursuing an attractive orphan regulatory pathway. -----
Uveitis
Program: VT1908 Eye Drops Status: Preclinical Development
Uveitis is a leading cause of blindness, with current treatments dominated by steroids—yet many patients are non-responders or steroid-incompatible due to side effects and contraindications.
VT1908 is a novel sterile eye drop that:
- Inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme driving immune cell activity.
- Demonstrated comparable efficacy to steroids in preclinical uveitis models.
- Offers a promising alternative for patients who cannot tolerate existing therapies.
This program is advancing toward clinical development with the potential to redefine treatment standards in immune-related eye disease.
Grab Source And More Here: HIND Website. -----
And as I mentioned earlier in the report, (Nasdaq: HIND) has several potential catalysts on our radar. Take a look:
#1. HIND Potential Catalyst - A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.
According to the Finviz website, HIND has a very low float.
In fact, the website reports this profile to have approximately 670K shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the 2nd half of 2025, could it create a near term spark? -----
#2. HIND Potential Catalyst - Oversold Leaning Technicals May Suggest A Healthy Reversal/Bounce Could Be Approaching.
At 3:00PM EST Tuesday, Barchart was reporting HIND to have several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 3:00PM EST Tuesday):
- 9-Day Relative Strength Index: 25.58%
- 14-Day Relative Strength Index: 33.95%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 0.58%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
#3. HIND Potential Catalyst - Positive Interim Data From Key Phase 2 Study Helps Vyome Come That Much Closer To A Breakthrough Treatment.
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW Market Opp.
VT-1953 continues to significantly improve the primary endpoint
Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference
VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality of Life (P<0.001), both secondary and exploratory endpoints, respectively.
CAMBRIDGE, Mass., September 04, 2025--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage heal.thcare holding company, today announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds ("MFW"). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8, to share more about the preliminary results and the MFW market in advance of full results, which are expected in October 2026.
...
"Despite a large number of cancer patients suffering from the symptoms of MFW, there are no FDA-approved options for MFW," said Dr. Sengupta, Co-founder of Vyome and Associate Professor of Medicine at Harvard Medical School. "These early observations suggest VT-1953 is meeting the clinical benchmarks to advance further in clinical trials, and offer hope that a breakthrough treatment is potentially on the horizon for patients with MFW. I am excited to discuss our interim results further on Monday, September 8, 2025 as well as our plan for upcoming milestones for this particular application."
Venkat Nelabhotla, CEO of Vyome, stated: "We are excited with the interim efficacy signals and to share more about the MFW market opp. MFW is a large, unmet addressable potential market opp. of $1Bn in the United States alone, offering the opp. to clinically develop and commercialize VT-1953 to positively impact patient lives. Based on our data, Vyome anticipates interacting with the FDA in early 2026. I look forward to advancing this program as part of our broader chronic immune-inflammation portfolio."
...
Read the full article here. -----
#4. HIND Potential Catalyst - A Signed MoU Sets Vyome On A Path To Jointly Pursue A Booming Global AI-Enabled Med-Device Market.
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
Vyome seeks to access multi-Bn-dollar AI-enabled medical device market
CAMBRIDGE, Mass. & PUNE, India, August 21, 2025--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND), ..., and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome's heal.thcare industry experience and resources with Embryyo's medical technology capabilities to potentially productize and commercialize smart medical devices that can transform the standard-of-care in disease management and treatment.
"Vyome's vision is to partner with the smartest talent tackling the biggest heal.thcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opp. and the Embryyo team - helmed by Indian Institutes of Technology (IIT) alums - has been working in this sector for a decade. We will be working with them to identify the specific initiatives on which we will partner," said Krishna Gupta, Chairman of Vyome Holdings.
...
Read the full article here. -----
#5. HIND Potential Catalyst - Visibility Help Could Grow Significantly With Vyome's Addition To The Nasdaq Capital Market.
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Celebrates Indian Independence Day by Honoring the US-India Innovation Partnership
CAMBRIDGE, Mass., August 15, 2025--(BUSINESS WIRE)--Vyome Holdings (Nasdaq: HIND), ..., will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as "HIND." The occasion will also mark India’s 79th Independence Day.
"The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our st-ock being on Nasdaq," said Krishna Gupta, Chairman of Vyome. "Our commitment to shareholders is simple: every decision we make will be in their best interests because we have no debt and because our board is smart and heavily aligned with shareholders."
"Our innovation pipeline is very deep and we have access to world-class talent in both the US and India," said Shiladitya Sengupta, Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. "Our immediate focus will be to unlock the value of our clinical stage assets that all revolve around major unmet needs in the $100Bn immuno-inflammatory market, but our vision extends well beyond that."
...
Read the full article here. -----
(Nasdaq: HIND) Recap - 5 Potential Catalysts Lead The Way!
#1. A Tiny Float Could Create A Serious Environment For Heightened Volatility Potential.
#2. Oversold Leaning Technicals May Suggest A Healthy Reversal/Bounce Could Be Approaching.
#3. Positive Interim Data From Key Phase 2 Study Helps Vyome Come That Much Closer To A Breakthrough Treatment.
#4. A Signed MoU Sets Vyome On A Path To Jointly Pursue A Booming Global AI-Enabled Med-Device Market.
#5. Visibility Help Could Grow Significantly With Vyome's Addition To The Nasdaq Capital Market. -----
Coverage is now officially kicked-off on Vyome Holdings, Inc. (Nasdaq: HIND).
Be on your toes and keep your eyes peeled for updates coming soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/16/2025 and ending on 09/17/2025 to publicly disseminate information about (HIND:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (HIND:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/hind-1nyww/#details | 
